Astria Therapeutics Inc Newsroom

LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $23

Moomoo NewsDec 11 15:31 ET · Ratings

Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Raises Target Price to $32

Moomoo NewsDec 11 12:31 ET · Ratings

Express News | Astria Therapeutics: Advancing Navenibart to Phase 3 Development With Trial Initiation Expected in Q1 2025

ReutersDec 11 08:02 ET

Express News | Astria Therapeutics Inc - Navenibart Shows Favorable Safety and Well-Tolerated Profile

ReutersDec 11 08:01 ET

Astria Therapeutics Announces Positive Final Results From Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

Business WireDec 11 08:00 ET

Express News | Astria Therapeutics Announces Positive Final Results From Target Enrollment in the Alpha-Star Phase 1B/2 Trial of Navenibart for Hae

ReutersDec 11 08:00 ET

Astria Therapeutics Announces FDA Clearance Of IND Application For STAR-0310, A Monoclonal Antibody OX40 Antagonist For The Treatment Of Atopic Dermatitis

BenzingaDec 10 08:06 ET

Express News | Astria Therapeutics Inc: Phase 1a Trial of Star-0310 in Healthy Volunteers Expected to Initiate in Q1 2025

ReutersDec 10 08:00 ET

Express News | Astria Therapeutics Announces FDA Clearance of Ind Application for Star-0310, a Monoclonal Antibody Ox40 Antagonist for the Treatment of Atopic Dermatitis

ReutersDec 10 08:00 ET

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BusinesswireDec 3 16:10 ET

Express News | Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersDec 3 16:10 ET

TD Cowen Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $35

Moomoo NewsNov 20 07:33 ET · Ratings

Astria Therapeutics (NASDAQ:ATXS) Is In A Good Position To Deliver On Growth Plans

Simply Wall StNov 18 08:36 ET

A Quick Look at Today's Ratings for Astria Therapeutics Inc(ATXS.US), With a Forecast Between $23 to $35

Moomoo NewsNov 15 08:00 ET · Ratings

12 Health Care Stocks Moving In Thursday's Pre-Market Session

BenzingaNov 14 16:10 ET

Astria Therapeutics Analyst Ratings

BenzingaNov 14 08:16 ET · Ratings

Express News | Astria Therapeutics : Oppenheimer Raises Target Price to $28 From $26

ReutersNov 14 08:07 ET

H.C. Wainwright Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsNov 14 06:31 ET · Ratings

Express News | Astria Therapeutics Q3 EPS $(0.42) Misses $(0.41) Estimate

BenzingaNov 13 16:37 ET

Astria Expects Cash, Cash Equivalents and Short-Term Investments as of Sept 30 Sufficient to Fund Ops Into Mid-2027 >ATXS

Dow JonesNov 13 16:21 ET